Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 4 (2007), Issue 5 (May)

1. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
   Mov Disord, 22(5): 720-2. [Abstract] [Full-text]
2. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
   Clin Cancer Res, 13(9): 2745-50. [Abstract] [Full-text]
3. Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease.
   Clin Cancer Res, 13(9): 2658-66. [Abstract] [Full-text]
4. T-cell distribution and adhesion receptor expression in metastatic melanoma.
   Clin Cancer Res, 13(9): 2549-56. [Abstract] [Full-text]
5. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.
   Hum Gene Ther, 18(4): 379-86. [Abstract] [Full-text]
6. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes.
   Biomaterials, 28(21): 3255-62. [Abstract] [Full-text]
7. Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice.
   Hum Gene Ther, 18(4): 323-32. [Abstract] [Full-text]
8. Accuracy of choroidal melanoma diagnosis by general ophthalmologists: a prospective study.
   Eye, 21(5): 595-7. [Abstract] [Full-text]
9. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy?
   Expert Opin Biol Ther, 7(5): 577-86. [Abstract] [Full-text]
10. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Cancer Res, 67(9): 4499-506. [Abstract] [Full-text]
11. Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin.
    Cancer Res, 67(9): 4353-63. [Abstract] [Full-text]
12. Metastatic melanoma to the kidney presenting with renal vein tumor thrombus.
    Urology, 69(5): 982.e7-9. [Abstract] [Full-text]
13. Rewired ERK-JNK signaling pathways in melanoma.
    Cancer Cell, 11(5): 447-60. [Abstract] [Full-text]
14. Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis.
    J Biol Chem, 282(19): 14140-7. [Abstract] [Full-text]
15. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.
    Hum Mutat, 28(6): 578-88. [Abstract] [Full-text]
16. Expression of GAGE family proteins in malignant melanoma.
    Cancer Lett, 251(2): 258-67. [Abstract] [Full-text]
17. Hyperfluidization-coupled membrane microdomain reorganization is linked to activation of the heat shock response in a murine melanoma cell line.
    Proc Natl Acad Sci U S A, 104(19): 7945-50. [Abstract] [Full-text]
18. DNA mismatch repair protein expression and microsatellite instability in primary mucosal melanomas of the head and neck.
    Histopathology, 50(6): 780-8. [Abstract] [Full-text]
19. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients.
    Histopathology, 50(6): 764-72. [Abstract] [Full-text]
20. Novel inhibitors in the treatment of metastatic melanoma.
    Expert Rev Anticancer Ther, 7(5): 715-24. [Abstract] [Full-text]
21. New approaches in metastatic melanoma: biological and molecular targeted therapies.
    Expert Rev Anticancer Ther, 7(5): 701-13. [Abstract] [Full-text]
22. Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness.
    Melanoma Res, 17(2): 131-6. [Abstract] [Full-text]
23. The melanoma epidemic debate: some evidence for a real phenomenon from Tuscany, Italy.
    Melanoma Res, 17(2): 129-30. [Abstract] [Full-text]
24. Diagnosis and treatment of cutaneous melanoma: state of the art 2006.
    Melanoma Res, 17(2): 117-27. [Abstract] [Full-text]
25. Molecular genetic analysis of NBS1 in German melanoma patients.
    Melanoma Res, 17(2): 109-16. [Abstract] [Full-text]
26. The Y152X MC1R gene mutation: occurrence in ethnically diverse Jewish malignant melanoma patients.
    Melanoma Res, 17(2): 105-8. [Abstract] [Full-text]
27. CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells.
    Melanoma Res, 17(2): 91-103. [Abstract] [Full-text]
28. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Melanoma Res, 17(2): 83-9. [Abstract] [Full-text]
29. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
    Melanoma Res, 17(2): 75-82. [Abstract] [Full-text]
30. Role of acidic cell organelles in the higher nonmelanoma retention of melanoma markers based on N-(2-dialkylaminoethyl)benzamides and the cytotoxicity of alkylating benzamides.
    Melanoma Res, 17(2): 61-73. [Abstract] [Full-text]
31. Simultaneous application of the vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 and ionizing radiation does not further reduce the growth of canine oral melanoma xenografts in nude mice.
    Vet J, 173(3): 564-70. [Abstract] [Full-text]
32. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study.
    Cancer, 109(8): 1570-8. [Abstract] [Full-text]
33. Influence of age on survival in childhood spitzoid melanomas.
    Cancer, 109(8): 1579-83. [Abstract] [Full-text]
34. Chemokine-mediated migration of melanoma cells towards lymphatics--a mechanism contributing to metastasis.
    Oncogene, 26(21): 2997-3005. [Abstract] [Full-text]
35. Sun-protective behaviors in families at increased risk of melanoma.
    J Invest Dermatol, 127(6): 1343-50. [Abstract] [Full-text]
36. Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma.
    J Invest Dermatol, 127(6): 1465-7. [Abstract] [Full-text]
37. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    Cancer Immunol Immunother, 56(8): 1251-64. [Abstract] [Full-text]
38. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.
    Cancer Immunol Immunother, 56(8): 1153-61. [Abstract] [Full-text]
39. Association of hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) and malignant melanoma in two patients.
    Melanoma Res, 17(3): 201-3. [Abstract] [Full-text]
40. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
    Melanoma Res, 17(3): 193-200. [Abstract] [Full-text]
41. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Melanoma Res, 17(3): 185-91. [Abstract] [Full-text]
42. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
    Melanoma Res, 17(3): 177-83. [Abstract] [Full-text]
43. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Melanoma Res, 17(3): 169-76. [Abstract] [Full-text]
44. The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis.
    Melanoma Res, 17(3): 155-68. [Abstract] [Full-text]
45. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm.
    Melanoma Res, 17(3): 147-54. [Abstract] [Full-text]
46. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Melanoma Res, 17(3): 139-45. [Abstract] [Full-text]
47. Reproductive history and cutaneous malignant melanoma: a comparison between women and men.
    Am J Epidemiol, 165(11): 1265-70. [Abstract] [Full-text]
48. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Oncogene, 26(23): 3364-77. [Abstract] [Full-text]
49. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.
    Cancer Res, 67(10): 5009-16. [Abstract] [Full-text]
50. Scavenger receptor-A negatively regulates antitumor immunity.
    Cancer Res, 67(10): 4996-5002. [Abstract] [Full-text]
51. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    J Clin Oncol, 25(15): 2078-85. [Abstract] [Full-text]
52. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
    Eur J Surg Oncol, 33(5): 627-32. [Abstract] [Full-text]
53. Primary malignant melanoma of the oral mucosa.
    J Oral Maxillofac Surg, 65(6): 1117-20. [Abstract] [Full-text]
54. Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
    Pigment Cell Res, 20(3): 216-21. [Abstract] [Full-text]
55. Melanoma invasion - current knowledge and future directions.
    Pigment Cell Res, 20(3): 161-72. [Abstract] [Full-text]
56. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study.
    Arch Otolaryngol Head Neck Surg, 133(5): 442-7. [Abstract] [Full-text]
57. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment.
    Am J Dermatopathol, 29(3): 237-41. [Abstract] [Full-text]
58. Metastatic myxoid melanoma with partial regression of the primary lesion.
    J Cutan Pathol, 34(6): 508-12. [Abstract] [Full-text]
59. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    J Cutan Pathol, 34(6): 448-55. [Abstract] [Full-text]
60. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Cancer, 109(9): 1855-62. [Abstract] [Full-text]
61. Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment.
    Blood, 109(11): 4777-85. [Abstract] [Full-text]
62. Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1.
    Oncogene, 26(24): 3521-31. [Abstract] [Full-text]
63. Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken.
    Int J Cancer, 121(2): 323-8. [Abstract] [Full-text]
64. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
    Int J Cancer, 121(2): 301-7. [Abstract] [Full-text]
65. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Int J Cancer, 121(2): 257-64. [Abstract] [Full-text]
66. Defective antitumor responses in CX3CR1-deficient mice.
    Int J Cancer, 121(2): 316-22. [Abstract] [Full-text]
67. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
    Appl Immunohistochem Mol Morphol, 15(2): 160-4. [Abstract] [Full-text]
68. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
    Am J Ophthalmol, 143(6): 958-969. [Abstract] [Full-text]
69. CPA melanoma: diagnosis and management.
    Otol Neurotol, 28(4): 529-37. [Abstract] [Full-text]
70. Capsule endoscopy in patients with malignant melanoma.
    Am J Gastroenterol, 102(6): 1204-8. [Abstract] [Full-text]
71. Melanoma incidence and mortality in Scotland 1979-2003.
    Br J Cancer, 96(11): 1772-7. [Abstract] [Full-text]
72. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
    PLoS Med, 4(5): e176. [Abstract] [Full-text]
73. Cryosurgical treatment of lentigo maligna.
    J Dtsch Dermatol Ges, 5(6): 477-80. [Abstract] [Full-text]
74. A potential predictive marker for response to interferon in malignant melanoma.
    J Dtsch Dermatol Ges, 5(6): 456-9. [Abstract] [Full-text]
75. Clinical role of 123I-IMP SPECT for the differential diagnosis of ocular malignant melanoma: a time-course analysis.
    Nucl Med Commun, 28(7): 567-73. [Abstract] [Full-text]
76. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients.
    Int J Cancer, 121(3): 689-93. [Abstract] [Full-text]
77. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model.
    Int J Cancer, 121(3): 666-74. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.